This gap in treatment is critical because between 30% and 50% of early-onset GBS is attributed to infants born to mothers who would fall into this group. 4 Another study concluded that a risk-factor approach would only identify less than 50% of the full-term infants who became septic. 5 We need an approach that identifies colonized women without risk factors.
The risk-factor approach also presents several disadvantages regarding the implementation of this approach. Effective treatment using the risk-factor approach requires that women with risk factors are identified. A recent report from the CDC found that approximately 70% of unscreened women who developed a risk factor did not receive intrapartum antibiotics. 6 This represents a large number of women who should have been treated according to the standards of care. So not only does the risk-based approach fail to identify a large number of women, but also a substantial number who do qualify for treatment are not being treated!
The antenatal screening option offers several advantages. The screening approach offers more complete coverage by combining strategies. The goal is to screen everyone; but for those who develop risk factors or whose results are unavailable, a risk factor approach is applied. This approach has been shown to be effective against the development of early-onset GBS disease. ''The risk-based approach has a predicted efficacy of 60% compared with the >90% predicted efficacy of the fully implemented culture-based approach'' (Ref. [7] , p. 973). More recent data showed a decrease in the prevalence of GBS sepsis from a prevalence of 1.16 per 1000 live births to a prevalence of 0.14 per 1000 live births after the institution of the CDC screening protocol. 8 While opponents of the culture approach argue that this strategy is more costly, the decreased incidence of early-onset GBS sepsis reduces costs by decreasing the expenses on antibiotics, other medications and the number of infants who would otherwise require aggressive treatment. 9 Therefore, the authors of one study concluded that the significant decrease they observed in GBS sepsis outweighs the cost of screening. 9 It is for all of the above reasons that I would like to encourage support of a universal screening approach. As a future Pediatric Nurse Practitioner, I plan to be involved by serving as an advocate for my patients, educating colleagues and patients on GBS, and collaborating with health professionals, especially those who are involved in the obstetrical management of patients. I urge other health care providers that are involved in either maternal or newborn care to do the same. In fact, the CDC 2 and the AAP 10 include advocacy and education as part of their recommendations. Patients should be informed of the prevention strategy employed by their providers and facility. In addition, individual requests for GBS cultures should be honored. By educating parents, they can be informed of the options available and choose a provider that will be consistent with their beliefs.
GBS guidelines also highlight the importance of collaboration. Open communication between clinicians and patients is needed to ensure prevention of GBS disease. Collaboration also includes working together to learn more about GBS and the best approach for our population. Our involvement should include being active in the research process and in establishing surveillance that will monitor the incidence of neonatal GBS disease, adverse reactions to antimicrobial prophylaxis and the emergence of perinatal infections caused by antibiotic-resistant 
